Prevalence of albicans and non-albicans candiduria in a malaysian medical centre

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: To determine the proportion of albicans and non-albicans candiduria in a hospital setting and to ascertain if fluconazole is still suitable as empirical antifungal therapy based on antifungal susceptibility patterns of Candida species.

Methods: The cross-sectional study was conducted between December 2010 and December 2011 at UKM Medical Centre, Kuala Lumpur, Malaysia and comprised 64 urine samples from patients who were either suspected or confirmed to have urinary tract infections. Yeasts were speciated using ID 32 C and subjected to antifungal susceptibility testing using Sensititre® YeastOne YO8.

Results: Candida albicans accounted for 38(59.4%) of the isolates, Candida tropicalis 18(28.1%), Candida glabrata 6(9.4%) and Candida parapsilosis 2(3.1%). Overall, the isolates were susceptible to both amphotericin B (MIC90 1μg/ml) and to 5-flucytosine (MIC90 0.25 μg/ml), but susceptible-dose dependent towards fluconazole (MIC90 16μg/ml). Individually, Candida albicans was susceptible to fluconazole (MIC90 2μg/ml), amphotericin B (MIC90 0.5μg/ml) and 5-flucytosine (MIC90 0.25μg/ml). Candida tropicalis was also susceptible to fluconazole (MIC90 4μg/ml), amphotericin B (MIC90 1μg/ml) and 5-flucytosine (MIC90 0.125μg/ml). Candida glabrata was resistant to fluconazole (MIC90 64μg/ml), but susceptible to amphotericin B (MIC90 1μg/ml) and 5-flucytosine (MIC90 0.125μg/ml). Lastly, Candida parapsilosis was resistant to fluconazole (MIC90 256μg/ml), but susceptible to amphotericin B (MIC90 0.5μg/ml) and 5-flucytosine (MIC90 0.5μg/ml).

Conclusion: The commonest yeast associated with candiduria at the study site was Candida albicans, and fluconazole can still be used for empirical therapy of candiduria.

Original languageEnglish
Pages (from-to)1375-1379
Number of pages5
JournalJournal of the Pakistan Medical Association
Volume64
Issue number12
Publication statusPublished - 1 Dec 2014

Fingerprint

Fluconazole
Flucytosine
Amphotericin B
Candida albicans
Candida
Candida tropicalis
Candida glabrata
Yeasts
Malaysia
Urinary Tract Infections
Cross-Sectional Studies
Urine
Therapeutics

Keywords

  • Candida
  • Candiduria
  • Fluconazole
  • ID 32 C
  • Sensititre

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{b0af340fa3fa4ffe83ae0d82f130d62a,
title = "Prevalence of albicans and non-albicans candiduria in a malaysian medical centre",
abstract = "Objective: To determine the proportion of albicans and non-albicans candiduria in a hospital setting and to ascertain if fluconazole is still suitable as empirical antifungal therapy based on antifungal susceptibility patterns of Candida species.Methods: The cross-sectional study was conducted between December 2010 and December 2011 at UKM Medical Centre, Kuala Lumpur, Malaysia and comprised 64 urine samples from patients who were either suspected or confirmed to have urinary tract infections. Yeasts were speciated using ID 32 C and subjected to antifungal susceptibility testing using Sensititre{\circledR} YeastOne YO8.Results: Candida albicans accounted for 38(59.4{\%}) of the isolates, Candida tropicalis 18(28.1{\%}), Candida glabrata 6(9.4{\%}) and Candida parapsilosis 2(3.1{\%}). Overall, the isolates were susceptible to both amphotericin B (MIC90 1μg/ml) and to 5-flucytosine (MIC90 0.25 μg/ml), but susceptible-dose dependent towards fluconazole (MIC90 16μg/ml). Individually, Candida albicans was susceptible to fluconazole (MIC90 2μg/ml), amphotericin B (MIC90 0.5μg/ml) and 5-flucytosine (MIC90 0.25μg/ml). Candida tropicalis was also susceptible to fluconazole (MIC90 4μg/ml), amphotericin B (MIC90 1μg/ml) and 5-flucytosine (MIC90 0.125μg/ml). Candida glabrata was resistant to fluconazole (MIC90 64μg/ml), but susceptible to amphotericin B (MIC90 1μg/ml) and 5-flucytosine (MIC90 0.125μg/ml). Lastly, Candida parapsilosis was resistant to fluconazole (MIC90 256μg/ml), but susceptible to amphotericin B (MIC90 0.5μg/ml) and 5-flucytosine (MIC90 0.5μg/ml).Conclusion: The commonest yeast associated with candiduria at the study site was Candida albicans, and fluconazole can still be used for empirical therapy of candiduria.",
keywords = "Candida, Candiduria, Fluconazole, ID 32 C, Sensititre",
author = "Ding, {Chuan Hun} and {Abdul Wahab}, Asrul and {Abdul Samat}, {Muttaqillah Najihan} and Khaithir, {Tzar Mohd Nizam}",
year = "2014",
month = "12",
day = "1",
language = "English",
volume = "64",
pages = "1375--1379",
journal = "JPMA. The Journal of the Pakistan Medical Association",
issn = "0030-9982",
publisher = "Pakistan Medical Association",
number = "12",

}

TY - JOUR

T1 - Prevalence of albicans and non-albicans candiduria in a malaysian medical centre

AU - Ding, Chuan Hun

AU - Abdul Wahab, Asrul

AU - Abdul Samat, Muttaqillah Najihan

AU - Khaithir, Tzar Mohd Nizam

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Objective: To determine the proportion of albicans and non-albicans candiduria in a hospital setting and to ascertain if fluconazole is still suitable as empirical antifungal therapy based on antifungal susceptibility patterns of Candida species.Methods: The cross-sectional study was conducted between December 2010 and December 2011 at UKM Medical Centre, Kuala Lumpur, Malaysia and comprised 64 urine samples from patients who were either suspected or confirmed to have urinary tract infections. Yeasts were speciated using ID 32 C and subjected to antifungal susceptibility testing using Sensititre® YeastOne YO8.Results: Candida albicans accounted for 38(59.4%) of the isolates, Candida tropicalis 18(28.1%), Candida glabrata 6(9.4%) and Candida parapsilosis 2(3.1%). Overall, the isolates were susceptible to both amphotericin B (MIC90 1μg/ml) and to 5-flucytosine (MIC90 0.25 μg/ml), but susceptible-dose dependent towards fluconazole (MIC90 16μg/ml). Individually, Candida albicans was susceptible to fluconazole (MIC90 2μg/ml), amphotericin B (MIC90 0.5μg/ml) and 5-flucytosine (MIC90 0.25μg/ml). Candida tropicalis was also susceptible to fluconazole (MIC90 4μg/ml), amphotericin B (MIC90 1μg/ml) and 5-flucytosine (MIC90 0.125μg/ml). Candida glabrata was resistant to fluconazole (MIC90 64μg/ml), but susceptible to amphotericin B (MIC90 1μg/ml) and 5-flucytosine (MIC90 0.125μg/ml). Lastly, Candida parapsilosis was resistant to fluconazole (MIC90 256μg/ml), but susceptible to amphotericin B (MIC90 0.5μg/ml) and 5-flucytosine (MIC90 0.5μg/ml).Conclusion: The commonest yeast associated with candiduria at the study site was Candida albicans, and fluconazole can still be used for empirical therapy of candiduria.

AB - Objective: To determine the proportion of albicans and non-albicans candiduria in a hospital setting and to ascertain if fluconazole is still suitable as empirical antifungal therapy based on antifungal susceptibility patterns of Candida species.Methods: The cross-sectional study was conducted between December 2010 and December 2011 at UKM Medical Centre, Kuala Lumpur, Malaysia and comprised 64 urine samples from patients who were either suspected or confirmed to have urinary tract infections. Yeasts were speciated using ID 32 C and subjected to antifungal susceptibility testing using Sensititre® YeastOne YO8.Results: Candida albicans accounted for 38(59.4%) of the isolates, Candida tropicalis 18(28.1%), Candida glabrata 6(9.4%) and Candida parapsilosis 2(3.1%). Overall, the isolates were susceptible to both amphotericin B (MIC90 1μg/ml) and to 5-flucytosine (MIC90 0.25 μg/ml), but susceptible-dose dependent towards fluconazole (MIC90 16μg/ml). Individually, Candida albicans was susceptible to fluconazole (MIC90 2μg/ml), amphotericin B (MIC90 0.5μg/ml) and 5-flucytosine (MIC90 0.25μg/ml). Candida tropicalis was also susceptible to fluconazole (MIC90 4μg/ml), amphotericin B (MIC90 1μg/ml) and 5-flucytosine (MIC90 0.125μg/ml). Candida glabrata was resistant to fluconazole (MIC90 64μg/ml), but susceptible to amphotericin B (MIC90 1μg/ml) and 5-flucytosine (MIC90 0.125μg/ml). Lastly, Candida parapsilosis was resistant to fluconazole (MIC90 256μg/ml), but susceptible to amphotericin B (MIC90 0.5μg/ml) and 5-flucytosine (MIC90 0.5μg/ml).Conclusion: The commonest yeast associated with candiduria at the study site was Candida albicans, and fluconazole can still be used for empirical therapy of candiduria.

KW - Candida

KW - Candiduria

KW - Fluconazole

KW - ID 32 C

KW - Sensititre

UR - http://www.scopus.com/inward/record.url?scp=84928347575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928347575&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 1375

EP - 1379

JO - JPMA. The Journal of the Pakistan Medical Association

JF - JPMA. The Journal of the Pakistan Medical Association

SN - 0030-9982

IS - 12

ER -